The RNASE1 antibody is a crucial tool for detecting ribonuclease A1 (RNASE1), a member of the vertebrate-specific RNase A superfamily involved in RNA metabolism, angiogenesis, and host defense. RNASE1. primarily secreted by the pancreas, cleaves single-stranded RNA and exhibits antimicrobial and antiviral properties. Dysregulation of RNASE1 has been linked to pathologies such as cancer, inflammatory disorders, and neurodegenerative diseases. Researchers use RNASE1 antibodies (polyclonal or monoclonal, often raised in rabbits or mice) to investigate its expression, localization, and function in tissues or cell lines via techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), or ELISA. These antibodies typically target specific epitopes, such as the N-terminal or catalytic domains, and are validated for specificity using knockout controls or peptide-blocking assays. In translational studies, RNASE1 antibodies aid in exploring its role in tumor angiogenesis, endothelial dysfunction, or immune responses, with potential diagnostic or therapeutic implications. Recent studies also highlight its dual role in promoting inflammation resolution and tissue repair. Validating antibody performance across experimental conditions remains essential to ensure reliability in both basic research and clinical applications.